Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026

Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026

Real-World Evidence to be Presented Comparing First-Line Lenvatinib Versus Dabrafenib Plus Trametinib in BRAF-Mutated Differentiated Thyroid Cancer Additional Analysis from the Pivotal Phase 3 CLEAR Trial Examines Efficacy Outcomes by Patterns of Progression in Advanced Renal Cell…


Read original release

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *